Dr Chandra Kirana

My Research :
Dr Chandra Kirana's research interest focus on finding biomarkers for bowel cancer patients using proteomic approaches. Almost 90% of bowel cancer patients died from metastatic dissemination mostly to the liver. Protein biomarkers are urgently required to support current methodologies to improve accuracy in stratifying patients into low and high risk of metastasis so that accurate disease management will be given to the patients to increase survival. In addition, she is also interested in using the concept of "seed and soil" to understand the mechanism of metastatic dissemination of colorectal cancer to the liver. Her work equipped with a large number of samples from bowel cancer patients completed with clinical parameters of the patients and the histology of tumours. She also has experience in isolation and identification of bio-active compounds from medicinal plants using various chromatographic and spectrophotometric techniques. Her previous work involved using small animals to assess efficacy of active compounds isolated from medicinal plants including AOM-induced colon cancer and DSS-induced inflammatory bowel disease model study.

Collaborations:
Clinicians at The Queen Elizabeth Hospital and Royal Adelaide Hospital
Mr John Keating, Wellington Hospital, Wellington, New Zealand
Professor Richard Stubbs, P3 Research, Wellington, New Zealand
Dr Lifeng Peng, Centre for Biodiscovery, School of Biological Sciences, Victoria University of Wellington, Wellington, New Zealand
Dr Andrea Bubendorfer, Callaghan Innovation, New Zealand's Innovation Agency, Wellington, New Zealand

Consumer Engagement:
Cancer Voices SA